208 related articles for article (PubMed ID: 19383347)
1. MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S.
Bénard J; Raguénez G; Kauffmann A; Valent A; Ripoche H; Joulin V; Job B; Danglot G; Cantais S; Robert T; Terrier-Lacombe MJ; Chassevent A; Koscielny S; Fischer M; Berthold F; Lipinski M; Tursz T; Dessen P; Lazar V; Valteau-Couanet D
Mol Oncol; 2008 Oct; 2(3):261-71. PubMed ID: 19383347
[TBL] [Abstract][Full Text] [Related]
2. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
3. Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma.
Lavarino C; Cheung NK; Garcia I; Domenech G; de Torres C; Alaminos M; Rios J; Gerald WL; Kushner B; LaQuaglia M; Mora J
BMC Cancer; 2009 Feb; 9():44. PubMed ID: 19192278
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age.
Taggart DR; London WB; Schmidt ML; DuBois SG; Monclair TF; Nakagawara A; De Bernardi B; Ambros PF; Pearson AD; Cohn SL; Matthay KK
J Clin Oncol; 2011 Nov; 29(33):4358-64. PubMed ID: 21969516
[TBL] [Abstract][Full Text] [Related]
5. Epithelial-mesenchymal transition-related gene expression as a new prognostic marker for neuroblastoma.
Nozato M; Kaneko S; Nakagawara A; Komuro H
Int J Oncol; 2013 Jan; 42(1):134-40. PubMed ID: 23135478
[TBL] [Abstract][Full Text] [Related]
6. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.
Chen QR; Bilke S; Wei JS; Whiteford CC; Cenacchi N; Krasnoselsky AL; Greer BT; Son CG; Westermann F; Berthold F; Schwab M; Catchpoole D; Khan J
BMC Genomics; 2004 Sep; 5():70. PubMed ID: 15380028
[TBL] [Abstract][Full Text] [Related]
7. Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma.
Lee E; Lee JW; Lee B; Park K; Shim J; Yoo KH; Koo HH; Sung KW; Park WY
BMC Med Genomics; 2020 Nov; 13(1):171. PubMed ID: 33172452
[TBL] [Abstract][Full Text] [Related]
8. Stage 4S neuroblastoma tumors show a characteristic DNA methylation portrait.
Decock A; Ongenaert M; De Wilde B; Brichard B; Noguera R; Speleman F; Vandesompele J
Epigenetics; 2016 Oct; 11(10):761-771. PubMed ID: 27599161
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of MYCN amplified, progressive stage 4S neuroblastoma in a neonate with hepatic artery embolization in addition to multimodality treatment.
Boztug K; Kiely E; Roebuck DJ; Gaze M; Begent J; Brock P; Michalski A
Pediatr Blood Cancer; 2006 Feb; 46(2):253-7. PubMed ID: 15926157
[TBL] [Abstract][Full Text] [Related]
10. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).
Schleiermacher G; Michon J; Ribeiro A; Pierron G; Mosseri V; Rubie H; Munzer C; Bénard J; Auger N; Combaret V; Janoueix-Lerosey I; Pearson A; Tweddle DA; Bown N; Gerrard M; Wheeler K; Noguera R; Villamon E; Cañete A; Castel V; Marques B; de Lacerda A; Tonini GP; Mazzocco K; Defferrari R; de Bernardi B; di Cataldo A; van Roy N; Brichard B; Ladenstein R; Ambros I; Ambros P; Beiske K; Delattre O; Couturier J
Br J Cancer; 2011 Dec; 105(12):1940-8. PubMed ID: 22146831
[TBL] [Abstract][Full Text] [Related]
11. High genomic instability predicts survival in metastatic high-risk neuroblastoma.
Stigliani S; Coco S; Moretti S; Oberthuer A; Fischer M; Theissen J; Gallo F; Garavent A; Berthold F; Bonassi S; Tonini GP; Scaruffi P
Neoplasia; 2012 Sep; 14(9):823-32. PubMed ID: 23019414
[TBL] [Abstract][Full Text] [Related]
12. Bilateral adrenal primary tumor in Stage 4S neuroblastoma: The Italian experience and review of the literature.
Montalto S; Sertorio F; Podda M; Sorrentino S; Di Cataldo A; Provenzi M; Nonnis A; D'Ippolito C; Corrias MV; De Bernardi B
Pediatr Hematol Oncol; 2022 Aug; 39(5):441-452. PubMed ID: 35139733
[TBL] [Abstract][Full Text] [Related]
13. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
14. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature.
Tomioka N; Oba S; Ohira M; Misra A; Fridlyand J; Ishii S; Nakamura Y; Isogai E; Hirata T; Yoshida Y; Todo S; Kaneko Y; Albertson DG; Pinkel D; Feuerstein BG; Nakagawara A
Oncogene; 2008 Jan; 27(4):441-9. PubMed ID: 17637744
[TBL] [Abstract][Full Text] [Related]
15. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
16. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.
Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E
Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175
[TBL] [Abstract][Full Text] [Related]
17. Management of stage 4S composite neuroblastoma with a MYCN-amplified nodule.
Bishop MW; Yin H; Shimada H; Towbin AJ; Miethke A; Weiss B
J Pediatr Hematol Oncol; 2014 Jan; 36(1):e31-5. PubMed ID: 23528904
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
[TBL] [Abstract][Full Text] [Related]
19. Regulation of MYCN expression in human neuroblastoma cells.
Jacobs JF; van Bokhoven H; van Leeuwen FN; Hulsbergen-van de Kaa CA; de Vries IJ; Adema GJ; Hoogerbrugge PM; de Brouwer AP
BMC Cancer; 2009 Jul; 9():239. PubMed ID: 19615087
[TBL] [Abstract][Full Text] [Related]
20. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
